A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PARALLEL-GROUP TREATMENT, PHASE 2, DOUBLE-BLIND STUDY OF ONCE-WEEKLY SUBCUTANEOUS LY3457263 COMPARED TO PLACEBO IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS ON A STABLE DOSE OF SEMAGLUTIDE OR TIRZEPATIDE WHO FAILED TO ACHIEVE HBA1C GOAL

Intervention/treatment:
NISOTIROSTIDE (LY3457263) / TIRZEPATIDE (LY3298176) / SEMAGLUTIDE
Medical condition:
TYPE 2 DIABETES
Protocol code:
J1R-MC-GZFD
Control number:
295911
Status:
Recruiting
Approved:
May 02, 2025
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT06897475
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 75 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Role
CONTACT
Phone:
1-317-615-4559
Name
Physicians interested in becoming principal investigators please contact
Role
CONTACT
Sponsor
ELI LILLY CANADA INC

Locations

Bluewater Clinical Research Group Inc.
Sarnia, N7T 4X3
RECRUITING
Role
CONTACT
Phone:
1 (519) 344-6612
Name
John O'Mahony
Role
PRINCIPAL_INVESTIGATOR
Centricity Research Brampton Endocrinology
Brampton, L6S 0C6
RECRUITING
Role
CONTACT
Phone:
905 595 0560
Name
Harpreet Bajaj
Role
PRINCIPAL_INVESTIGATOR
Diabetes Heart Research Centre
Toronto, M6G 1M2
RECRUITING
Role
CONTACT
Phone:
4169245871
Name
Luis Noronha
Role
PRINCIPAL_INVESTIGATOR
Ecogene-21
Chicoutimi, G7H 7K9
RECRUITING
Role
CONTACT
Phone:
418-545-1252
Name
Daniel Gaudet
Role
PRINCIPAL_INVESTIGATOR
Fadia El Boreky Medicine
Waterloo, N2J 1C4
RECRUITING
Role
CONTACT
Phone:
519-569-7592
Name
Fadia El Boreky
Role
PRINCIPAL_INVESTIGATOR
G A Research Associates
Moncton, E1G 1A7
RECRUITING
Role
CONTACT
Phone:
506-852-9865
Name
Jocelyn Cormier
Role
PRINCIPAL_INVESTIGATOR
Maple Leaf Research
Toronto, M5G 1K2
RECRUITING
Role
CONTACT
Phone:
4164657936
Name
Graham Smith
Role
PRINCIPAL_INVESTIGATOR
Viacar Recherche Clinique
Longueuil, J4H 4B9
RECRUITING
Name
Genevieve Mathieu
Role
PRINCIPAL_INVESTIGATOR
Phone:
365-366-6267
Winterberry Research Inc.
Hamilton, L8J 0B6
RECRUITING
Role
CONTACT
Phone:
365-366-6267
Name
Steven Zizzo
Role
PRINCIPAL_INVESTIGATOR
Did you find what you were looking for?